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Background: Financial relationships between physicians and industry are extensive and public reporting of industry
payments to physicians is now occurring. Our objectives were to describe physician recipients of large total
payments from these seven companies, and to examine discrepancies between these payments and conflict of
interest (COI) disclosures in authors’ concurrent publications.
Methods: The investigative journalism organization, ProPublica, compiled the Dollars for Docs database of
payments to individuals from publically available data from seven US pharmaceutical companies during the period
2009 to 2010. We examined the cohort of 373 physicians in this database who each received USD $100,000 or
more in the reporting period 2009 to 2010.
Results: These physicians received a total of $52,600,624 during this period (mean payment per physician
$141,020). The predominant specialties were internal medicine and psychiatry. 147 of these physicians authored a
total of 134 publications in the first quarter of 2011 and 77% (103) of these publications provided a
COI disclosure. 69% of the 103 publications did not contain disclosures of the payment listed in the Dollars
for Docs database.
Conclusions: With increased public reporting of industry payments to physicians, it is apparent that large sums
are being paid for services such as consulting and peer education. In over two-thirds of publications where COI
disclosures were provided, the disclosures by physician authors did not include industry payments that were
documented in the Dollars for Docs database.
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Financial relationships between physicians and industry
are extensive in the U.S. [1,2], encompassing research
funding to individuals and institutions, personal financial
investments, and direct payments to physicians for ser-
vices such as consulting, advising, speaking engage-
ments, travel, and gifts. These financial relationships
may represent conflicts of interest (COI) and thus can* Correspondence: norriss@ohsu.edu
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reproduction in any medium, provided the ordiminish the credibility of clinicians, researchers,
research studies, and academic and other institutions
that receive such payments. In addition, both funder
and author conflicts are associated with bias in the
results of research studies [3-7] and derivative products
such as systematic reviews [8] and clinical practice
guidelines [9].
Concern over COI and resultant risk of bias has
engendered a variety of approaches and policies by bio-
medical journals, academic institutions, medical and
continuing education institutions, healthcare delivery
systems, professional organizations, and public sector
policy makers. Central to COI policies is disclosure, andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and increased transparency. One such policy in the US
is the Physician Payments Sunshine Act, signed into law
in the US in 2010 as part of the Patient Protection and
Affordable Care Act. This policy requires that pharma-
ceutical, medical device, biological, and medical supply
manufacturers report to the U.S. Department of Health
and Human Services payments that are more than
$10 to physicians and teaching hospitals [10]. The
law will require data reporting beginning in January
2013, including stock options, royalties, consulting fees,
honoraria, education, research grants, meals, gifts, enter-
tainment, and travel. In addition, the database will pro-
vide information on the physician receiving the
payment, their address, payment date, and drug or de-
vice that the physician helped promote. There will be
stiff penalties for both inadvertent lapses (up to
$150,000 annually for failure to report) and intentional
nondisclosure (up to $1 million annually) [10].
To date, drug companies have rarely disclosed pay-
ments to their speakers. Recently, however, a number
of companies have begun posting doctors’ names and
compensation on their web sites, some in anticipation of
the Sunshine Act, others a result of legal settlements
with the US government for illegal marketing of
pharmaceuticals [11].
The objectives of this study were to describe the phys-
ician recipients of large total payments from pharma-
ceutical companies and to examine discrepancies
between those payments and payee disclosures in con-
current publications. This study explores the feasibility,
utility, and limitations of using publically available pay-
ment data to examine these discrepancies.
Methods
The source of our payment data was the Dollars for
Docs database, developed by ProPublica, an investigative
journalism organization [11]. The Dollars for Docs
database (referred to as “the database”) was first
released October 18, 2010, containing about 30,000
discrete payments to approximately 17,000 US health
care providers by seven pharmaceutical companies over
varying numbers of quarters in 2009 and 2010. These
seven companies represented 36% of prescription drug
sales in the US in 2009 and disclosed $257.8 million in
payments to US healthcare providers [11]. Five of these
companies were required to make these disclosures by
the US Justice Department (AstraZeneca, Cephalon, Eli
Lilly, Johnson & Johnson, Pfizer); the other two (Merck,
GlaxoSmithKline) released these data voluntarily in
anticipation of the Sunshine Act.
ProPublica obtained these data from open-access web-
sites for each of the seven companies and aggregated
them into a single database. The original data wereavailable in a variety of formats, including unsortable
PDFs. ProPublica programming staff used a variety of
programs to scrape and clean the data, including Google
Refine [12], Firebug [13], Adobe Acrobat [14], and
others [15] to import these data into spreadsheets.
Names of payees varied, even within a single company’s
dataset, and Google Refine was used to aggregate the
data for each individual listed when variations in name
occurred such as the addition of an initial or an abbre-
viated first name. We verified the aggregation of data by
individuals in the Dollars for Docs database using the
Massachusetts General Hospital Utility Multiprogram-
ming System (MUMPS), reanalyzing the raw dataset
provided by ProPublica, and confirmed that our cohort
did receive the stipulated payments.
For each recipient of a payment from one of the seven
companies, the database includes the recipient’s name,
city and state, reason for the payment, company making
the payment, and the quarter(s) when the payment was
made. Companies varied in their categorization of the
reasons for payments, for example AstraZeneca and
Merck only reported payments to speakers, whereas Eli
Lilly, Cephalon and Pfizer reported payments for a var-
iety of services, including meals, travel, and consulting.
The exact date for the payments was not provided, and
companies varied in their aggregation of calendar quar-
ters. The database has been continuously updated since
its first release with the addition of more companies,
individuals, and payments. For this study, we used
payment data from the initial database, released in
October, 2010.
We selected as our study cohort individuals who
received more than USD $100,000 in the period 2009 to
2010. We chose this cohort of payees because the large
amounts of funds that these individuals received should
likely be remembered and disclosed in concurrent publi-
cations, and we felt that these payees may have charac-
teristics that make them somewhat homogeneous in
their behaviors. Among these individuals, we examined
only physicians, excluding other healthcare providers.
We obtained demographic information on the cohort,
including age, sex, years since medical school gradu-
ation, primary affiliation, specialty, and state of medical
board certification. These demographic data were
obtained from institutional websites, HealthGrades© and
a general Internet search. All data were entered into
Microsoft Access (Redmond, WA).
In order to examine whether physicians disclose these
payments, we identified publications by physicians in
our cohort in any authorship position by searching Med-
line from January 1, 2011 through March 31, 2011 using
the Ovid search engine. We included all types of publi-
cations (e.g., primary research studies, reviews, editor-
ials), and confined our search to English language
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brary (Carlsbad, CA). If we identified publications by
authors with similar names, we reviewed the full text to
further examine the institutional affiliation, credentials,
and subject matter of the article to determine if the indi-
vidual in our cohort authored the publication. If there
was any uncertainty about whether a physician in our
cohort authored a specific publication, a second member
of our research team independently examined the
publications and if there was disagreement, consensus
was achieved.
We then compared the COI disclosures to payments
made to those individuals as indicated in the Dollars for
Docs database. Because the lag time between completion
of the COI disclosure and the date of publication (both
electronic and print) is variable and unknown, and the
database does not contain exact payment dates, we com-
pared disclosures in 2011 publications to payments
received in 2009 and 2010. This should produce a con-
servative (low) estimate of discrepancies, as COI disclo-
sures in publications in 2011 should in all likelihood
include payments to those authors in the prior 2 years.
Since this is an observational, exploratory study, we
did not perform sample size calculations. Descriptive
statistics were used to summarize physician characteris-
tics, total payments, and discrepancies in disclosures. An
analysis of variance model was used to compare the
mean total payments among specialties with adequate
sample size (n > 20) and a linear regression model was
used to assess the association between total payments
and physician characteristics (age and sex). All analyses
were conducted using SAS 9.3 (SAS Institute Inc., Cary,
NC, USA).
Results and discussion
Of the 18,297 individuals listed in the database, 384 were
identified by ProPublica as earning $100,000 or more
during the time period 2009 to 2010 (Figure 1). Of
these 384 individuals, 373 (97%) were physicians; the14,021 individuals in the Dollars for Docs d
Individuals with total payme
Physicians (n=373)          N
Authors (n=147)    Non-authors (n=226)    
Figure 1 Study flow diagram. See text for details. Authors refer to individ
January to March 31, 2011.remaining 11 were pharmacists, nurses, and other
healthcare providers. The majority (89%) of these
physicians were male and the average age was 53 years
(median 53, range 36 to 75). The specialties most
frequently represented in the cohort were internal
medicine and psychiatry (each 31%).
The total payments to this physician cohort during the
reporting period were $52,600,624, with a mean payment
of $141,020 per physician (median $126,724, range
$100,047 to $303,558) (Table 1). The mean total
payment per physician per quarter for each company
ranged from $21,305 for GlaxoSmithKline to $3596 for
Johnson & Johnson. Payments were for consultation,
continuing education presentation, and other services.
None of the payments to this cohort of payees were
categorized as research funding.
For specialties with five or more physicians repre-
sented in our cohort, mean payments ranged from
$125,733 for psychiatry to $174,666 for anesthesiology.
Four specialties (family medicine, internal medicine, sur-
gery, and psychiatry) had 20 or more physicians repre-
sented in our cohort and the mean total payments per
physician per quarter were significantly different among
these specialties (P < 0.0001). In particular, the mean
total payment to physicians in internal medicine was sig-
nificantly higher than to physicians in family medicine
(mean difference $21,507; 95% confidence interval (CI)
$1,533 to $41,482) and to psychiatrists (mean difference
$25,623; 95% CI $13,176 to $38,069). The mean total
payment to surgeons was also significantly higher than
to psychiatrists (mean difference $27,990; 95% CI $6,750
to $49,229). The mean total payment to surgeons was
not significantly different from that to physicians in in-
ternal medicine ($153,722 vs. $151,356). Based on results
from the linear regression, the total payment per phys-
ician per quarter was not associated with sex
(P= 0.1730) or age (P= 0.4908).
147 of the 373 physicians published a total of 1223
articles between January 2009 and the end of March,atabase (version released October, 2010) 
nts > $100,000 (n=384) 
on-physicians (n=11) 
   Authors (n=5)      Non-authors (n=6) 
uals for whom we identified a publication within the period
Table 1 Total payments and payments per physician by specialty
Specialty Number of
physicians
Total payments (in USD) Mean payment per physician
(Standard Deviation) (In USD)
Primary care 145 21,286,443 146,803 (44,767)
Family medicine 28 3,635,749 129,848 (35,017)
Pediatrics 2 244,800 122,400 (18,243)
Internal medicine 115 17,405,894 151,356 (52,078)
Specialty medicine 75 10,955,643 146,075 (38,979)
Allergy and Immunology 15 2,384,175 158,945 (34,934)
Cardiovascular disease 6 916,441 152,740 (35,098)
Endocrinology, Diabetes, and Metabolism 10 1,432,020 143,202 (36,229)
Hematology 3 374,300 124,767 (21,104)
Neurology 14 2,154,235 153,874 (52,078)
Obstetrics and gynecology 14 1,795,064 128,219 (26,031)
Oncology 1 240,150 240,150 (0)
Pain Medicine 2 225,429 112,715 (6,353)
Physical Medicine and Rehabilitation 6 852,103 142,017 (28,489)
Pulmonology 3 459,552 153,184 (58,778)
Rheumatology 1 122,174 122,174 (0)
Surgery 24 3,689,339 153,722 (38,167)
Otolaryngology 2 300,500 150,250 (35,285)
Surgery 4 585,380 146,345 (50,171)
Urology 18 2,803,459 155,748 (37,879)
Psychiatry 117 14,710,749 125,733 (23,936)
Other 12 1,772,150 147,679 (54,067)
Anesthesiology 8 1,397,329 174,666 (62,088)
Emergency Medicine 1 165,800 165,800 (0)
Nuclear Medicine 1 101,246 101,246 (0)
Radiology 1 186,300 186,300 (0)
Information not found 1 107,775 107,775
Total: 373 Total payments: 52,600,624 Mean payment per
physician: 141,020 (39385)
Payments are aggregated across the seven pharmaceutical companies.
USD, U.S. dollar.
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range 1–125). Of the 134 publications by physicians in
the first quarter of 2011, 103 (77%) provided author dis-
closures of COI in the publication while the remaining
23% did not. Among publications with disclosures, 42
(41%) reported that the index author had nothing to dis-
close, while in 29 publications (28%) the author dis-
closed a conflict other than the payment in the Dollars
for Docs database. In the remaining 32 publications
(31%), the payment in the database was disclosed. The
percentage of publications with the payer in the Dollars
for Docs database disclosed, stratified by the 7 compan-
ies, is displayed in Figure 2.
In summary, among a cohort of physicians who were
known recipients of large total payments from a select
group of 7 pharmaceutical companies, nearly one-
quarter of their concurrent publications do not reportany COI disclosures. Furthermore, of the publications
with disclosure statements, over two-thirds do not re-
port payments listed in the Dollars for Docs database.
Several prior studies have examined the accuracy of
COI disclosures in journal publications, with similar
results. Two recent studies compared disclosures in pub-
lications to payment information from an orthopedic de-
vice company. Chimonas and colleagues [16] reported
high rates of nondisclosures: 50% among publications
directly or indirectly related to payments. Okike and
coauthors [17] reported rates of nondisclosure in pub-
lished abstracts from an orthopedic meeting of 20.7% for
payments that were directly related, and 50% for pay-
ments that were indirectly related to the topic of the ab-
stract. Other studies comparing abstracts and subsequent
publications or concurrent publications also suggest a
high prevalence of inaccurate author disclosures [18,19].
Figure 2 The relationship between disclosures in publications and known payments by pharmaceutical companies to physician
authors. Abbreviations: AZ, AstraZeneca; GSK, GlaxoSmithKline; J&J, Johnson & Johnson. Both the grey and black bars represent discrepancies
between the Dollars for Docs database and the physician author’s disclosures in publications. Dollars for Docs payment disclosed means that the
specific company that made a payment to the physician was listed in the author’s disclosures in the publication. Discrepancy in the conflict
disclosed means that one or more financial conflicts of interest were disclosed in the publication, but not the payer reported in the Dollars for
Docs database. No conflicts of interest disclosed means that the publication stated that there were no conflicts of interest despite the Dollars for
Docs database listing a payment.
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nated with payer databases, which were placed in the
public domain either voluntarily or by mandate of legal
settlements. The use of physician payment data from
pharmaceutical companies is novel, to our knowledge,
and our study provides insights into the methods, feasi-
bility, and limitations of using such datasets for studies
of discrepancies between payments known to have oc-
curred and disclosure in peer-reviewed journals. When
datasets are more complete and journal policies more
uniform, these approaches can be used to determine the
accuracy and completeness of disclosures.
Our study findings have important implications. Jour-
nal editors and readers rely on accurate disclosures by
authors in order to assess the credibility and risk of bias
in journal publications, and our findings suggest that the
accuracy and completeness of disclosures cannot be
assumed at present. As industry payment data increas-
ingly become publically available, however, journal staff
and readers will be able to verify the accuracy of author
disclosures. Though in the US, until the Sunshine Act is
implemented and there is a unified public reporting sys-
tem for industry payments to physicians, it may not be
feasible for journal editors and staff to check author dis-
closures. For authors, the increasing availability of pay-
ment data may promote more accurate disclosures or
may discourage physicians from accepting industrypayments, although there is as yet no evidence to sup-
port these possibilities. It is hoped that the standardized
reporting form of the International Committee of Med-
ical Journal Editors [20] will improve the accuracy of
disclosures, however such data are not yet available.
There are a number of limitations to this pilot work.
First, these are exploratory analyses on a small cohort of
American physicians, whose characteristics and behaviors
are likely not representative of US physicians in general,
including those who receive much smaller total payments
or those who do not receive funds from industry. Second,
the database that we examined was limited to the pay-
ments of only 7 pharmaceutical companies during variable
intervals in 2009 and 2010. The exact dates for payments
were not available, and the categorization of types of pay-
ments varied across companies, making comparisons of
the reasons for payments difficult.
Third, we faced challenges identifying publications
by our physician cohort: exact author names vary (e.g.,
use of middle initial or not) and can resemble names of
non-cohort authors. If we failed to identify all of the
author’s publications, we may bias our assessment of
rates of discrepancies if missing publications have a dif-
ferent disclosure rate than the rate in the publications
that we identified. There is a delay in indexing publica-
tions in Medline thus more recent publications may
have been missed.
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not be equated with inaccurate disclosures because of
several assumptions that we made. We did not examine
journal COI policies, but rather assumed that all jour-
nals required disclosures. We also did not examine how
journal COI policies address relevance of the topic of
the publication to the disclosure. We assumed that all
payments in the database should have been disclosed in
the identified publications.
It was difficult to determine the relationship between
the time of disclosure and payments as it was not possible
to know exactly when authors completed disclosures rela-
tive to the time of publication, as this varies widely across
journals. Although some journals request an update of
disclosures at the time of publication, it is unknown how
frequently authors comply and how accurate those
updates are. In addition, we only had information on the
quarter or group of quarters when payments occurred,
and not the exact dates. Although unlikely, we could have
overestimated rates of discrepancies if disclosure occurred
well prior to publication and prior to drug company pay-
ment, or if a disclosure was close to the publication date
and the required time period of disclosure was short, with
payment preceding the disclosure period. We feel that our
approach of examining 2011 publications should minimize
these biases, as disclosures in publications likely encom-
pass payments in the prior 2 years. Chimonas and collea-
gues [16] used a similar approach when they compared
payments to physicians by orthopedic device companies
to disclosures in orthopedic publications 1 to 2 years after
the payments were made.
Finally, we were unable to determine the reasons for
discrepancies, which are undoubtedly multifactorial, in-
cluding forgetting, carelessness, misreading or misinter-
preting COI policies, lack of clarity in disclosure forms,
or purposeful nonreporting. From these retrospective,
observational data we clearly cannot determine causality
or impute motive.
Future research can build on this work. Studies could
further describe the characteristics of physicians and
other healthcare professionals who accept payments
across a broad range of values and payment types. The
effectiveness of specific COI policies and disclosure
forms for achieving accurate and complete disclosures
should be explored for journals, institutional review
boards, academic institutions, and other organizations.
Predictors of the accuracy of COI disclosures can be
examined when more complete payment data are
available with implementation of the Sunshine Act
[10]. The effect of public disclosure of industry pay-
ments may be linked to provider behavior such as the
future acceptance of industry payments or the prescrip-
tion of specific medications when individual prescribing
data are available.Little is known about the effect of disclosure policies
and practices on the intended outcomes of improving
transparency and aiding in the interpretation of journal
articles. The dominant opinions in the literature are that
disclosures are essential because they enable the “readers
to form their own opinions on whether a conflict exists
and what relevance it has for the study” [21]. However
the evidence base for this opinion is scant. Readers may
find an article less interesting and valid [22] and a trial
less believable [23] if relevant industry relationships are
disclosed. On the other hand, when presented with a dir-
ect comparison of an abstract with and without an in-
dustry conflict disclosed, physician readers did not differ
significantly in their reported likelihood of prescribing
the new drug [24]. Further work is thus needed to deter-
mine how disclosures are interpreted and the informa-
tion used by the reader, and what constitutes optimal
presentation, level of detail, and relevance.
Conclusions
Transparency of industry payments to US physicians is
increasing because of new and anticipated government
policies and practices. Large amounts of money are
going to physicians from industry for non-research-
related services. In a small and select cohort of physi-
cians receiving large total payments from pharmaceutical
companies, there are discrepancies between payments
known to have occurred and disclosures in publications.
Journal editors need to continue to develop policies and
approaches that lead to accurate and complete disclo-
sures. Failure to accurately report financial relationships
with industry inhibits the ability of readers to assess the
credibility and risk of bias of publications.
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